Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) EBIT (2016 - 2026)

Viking Therapeutics (VKTX) has disclosed EBIT for 13 consecutive years, with -$164.1 million as the latest value for Q1 2026.

  • For Q1 2026, EBIT fell 195.89% year-over-year to -$164.1 million; the TTM value through Mar 2026 reached -$502.0 million, down 191.32%, while the annual FY2025 figure was -$393.3 million, 160.63% down from the prior year.
  • EBIT hit -$164.1 million in Q1 2026 for Viking Therapeutics, roughly flat from -$164.7 million in the prior quarter.
  • Across five years, EBIT topped out at -$16.2 million in Q3 2022 and bottomed at -$164.7 million in Q4 2025.
  • Average EBIT over 5 years is -$51.7 million, with a median of -$34.1 million recorded in 2024.
  • Year-over-year, EBIT fell 13.45% in 2022 and then crashed 256.28% in 2025.
  • Viking Therapeutics' EBIT stood at -$20.3 million in 2022, then crashed by 44.38% to -$29.3 million in 2023, then plummeted by 57.89% to -$46.2 million in 2024, then plummeted by 256.28% to -$164.7 million in 2025, then rose by 0.37% to -$164.1 million in 2026.
  • According to Business Quant data, EBIT over the past three periods came in at -$164.1 million, -$164.7 million, and -$98.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.